Mediark Joins Super-gap Startup 1000+ 'Micro DIPS'

MediArc, an innovator in the medical IT sector, has been officially recognized for its technological prowess and growth potential by being selected for Micro DIPS, a key program within the Ministry of SMEs and Startups' '2025 Super Gap Startup 1000+ Project'. Micro DIPS is a program where AI startups collaborate with demand-side institutions to plan AI transformation (AX) projects and verify them in real-world settings. Selected companies receive comprehensive support, ranging from commercialization funds to technology advancement and market expansion, to help AI-based innovative models successfully establish themselves in the market. At the core of MediArc is the AI-based healthcare system 'Simtomi'. This system integrates multi-language support with symptom analysis and summarization technology, allowing AI to precisely analyze and summarize user-inputted symptoms and effectively relay them to medical professionals. Notably, it supports 14 languages, aiming to break down language barriers and significantly enhance access to healthcare. This Micro DIPS selection provides an opportunity to directly apply and validate Simtomi's multi-language medical questionnaire and summarization system in clinical settings. This is expected to significantly contribute to bridging healthcare disparities caused by language barriers and helping patients access necessary medical services more easily and quickly. MediArc plans to continuously advance its core technologies, headquartered at its corporate research institute within Seoul Bio Hub, and successfully promote on-site proof-of-concept (PoC) through active collaboration with demand-side institutions. Furthermore, MediArc is expanding its international partnerships to countries like South Africa and Vietnam, thereby accelerating its entry into the global medical market. The ISO 17100 international translation standard certification and the patent for 'Method for providing AI-based multi-language medical questionnaire summarization and translation service' clearly demonstrate their unique technological capabilities and global competitiveness. MediArc CEO, Lee Chan-hyung, stated a strong ambition, saying, "Leveraging this opportunity, we will take the lead in resolving healthcare disparities beyond language and regional barriers with Simtomi's multi-language medical questionnaire and summarization capabilities," and "We will demonstrate MediArc's capabilities in the global market by disseminating innovative models verified through overseas partnerships and demonstrations." All eyes are on what positive changes MediArc's endeavors will bring to the global medical market.